Everest Medicines is a late-clinical biopharmaceutical company dedicated to licensing, developing, and commercializing innovative therapies around the world, with the goal of addressing critical unmet medical needs in Greater China and other emerging Asia-Pacific markets. Our world-class clinical and regulatory teams, insight-driven business development engine, and integrated commercial platform enable us to accelerate the delivery of innovative new medicines to patients. Since our establishment in 2017, we have brought together eight promising clinical-stage drug candidates for oncology, immunology, cardio-renal diseases, and infectious diseases. We target these four treatment areas based on the severity of unmet medical needs, the size of the high-risk patient population, and the emergence of innovative products around the world.